Institute for Research in Immunology and Cancer has secured funding from CECR, the same government agency that supported its launch ten years ago.
Institute for Research in Immunology and Cancer – Commercialization of Research (Iricor), an immuno-oncology drug commercialisation cluster based at Université de Montréal, secured C$25m ($19.2m) in Canadian government funding on Monday.
The injection of capital came from the government’s Centres of Excellence for Commercialization and Research (CECR) program, which builds links between researchers and business in core industries including health and the life sciences.
CECR previously provided Iricor with $15m in capital upon its founding in 2008.
Irico invests in…